One way to make protein-based vaccine is by injecting a virus’ genetic material to bacteria so that the latter produces spike protein, which are then harvested and turned into the vaccine.
You may take a look at other institutions that have developed Protein Subunit Vaccines.
You made a safe choice.
By the end of June 2020, dozens of institutions have already been developing their vaccines using this method. Novavax’s vaccine candidate has begun a phase II clinical trial.
You can choose the subunit vaccine or consider a different strategy.
Will you collaborate with Novavax or make your own vaccine.
Whoops, Indonesia does not have a cooperation agreement with Novavax, yet.
You can kick-start this cooperation.
While a cooperation is entirely feasible, its implementation is rather complicated. You must consider the benefits that could be gained through cooperation. Are you getting in to participate in the research, or just help with their clinical trials? You should also make sure that you will be in the list of priorities when the vaccine is ready.
If this is not your idea of a good strategy, you may seek alternatives or consider to develop a vaccine on your own.
You’ll start from a pretty much scratch. Are you sure you want to do this? Otherwise, would you rather collaborate with Novavax.
The Eijkman Institute for Molecular Biology is capable of developing protein-based vaccines and has been planning to do just that. Biofarma is ready for a collaboration. But the prototype of the protein-based vaccine may only become available in 2021. That’s way beyond your 12-months deadline to get a vaccine.
Seek out a different strategy.
Published:
Copyright 2020. Kompas.com
